Overview

To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids

Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
A Phase 1 study to assess pharmacokinetics (PK) and safety of abediterol 5 μg dry powder inhaler (DPI) given once daily (QD) for 9 days, compared to placebo, in patients with asthma on inhaled corticosteroids (ICSs).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca